Konturek S J, Brzozowski T, Radecki T, Dobrzańska M
Scand J Gastroenterol Suppl. 1984;92:91-6.
This study demonstrates that the suppression of thromboxane biosynthesis by OKY-1581, a selective inhibitor of thromboxane biosynthesis, prevents dose-dependently taurocholate-induced gastric mucosal necrosis and enhances the cytoprotective effect of low dose of taurocholate against mucosal necrosis by large dose of this agent. In all animals treated with OKY-1581, a decrease in mucosal generation of thromboxane was accompanied by an increased production of PGs probably due to availability of greater amounts of a common substrate in a cyclooxygenase pathway. This study provides direct evidence that gastric mucosa generates thromboxanes which may be involved in the pathogenesis of taurocholate-induced gastric mucosal lesions.
本研究表明，血栓素生物合成的选择性抑制剂OKY-1581对血栓素生物合成的抑制作用可剂量依赖性地预防牛磺胆酸盐诱导的胃黏膜坏死，并增强低剂量牛磺胆酸盐对大剂量该药物所致黏膜坏死的细胞保护作用。在用OKY-1581治疗的所有动物中，血栓素的黏膜生成减少，同时PGs生成增加，这可能是由于环氧化酶途径中更多共同底物的可用性所致。本研究提供了直接证据，表明胃黏膜会生成血栓素，其可能参与牛磺胆酸盐诱导的胃黏膜损伤的发病机制。
